Clinical trials: Bird Flu
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
- Trial name
- NCT00771615
- Testing
- GSK A/turkey H5N1 Influenza vaccine
- Where
- 10 sites in United States, Canada
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
H5N1 Influenza, H5N1 Virus
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
Given the recent circulation of avian influenza A(H5N1) clade 2.3.4.4b strains in birds and mammals in North America, Canada procured a supply of Arepanrix™ H5N1 for potential use in persons at high risk of highly pathogenic…
- Conditions
- H5N1 Influenza, H5N1 Virus, Avian Influenza, Avian Influenza A Virus
- Trial name
- NCT07275060
- Testing
- H5N1 vaccine (Arepanrix)
- Where
- 4 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
Influenza
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
- Trial name
- NCT01236040
- Testing
- GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A
- Where
- 4 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Avian Influenza
Safety and Pharmacokinetics Study of FBF001
The purpose of this study is to assess the clinical and laboratory safety and to determine the pharmacokinetic profile of FBF001.
- Trial name
- NCT02295813
- Testing
- FBF001
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fab'entech
Prepandemic Influenza Vaccine
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects
The present study will evaluate the immunogenicity, safety and tolerability of two doses of monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic…
- Trial name
- NCT00841646
- Testing
- Monovalent inactivated influenza vaccine
- Where
- 2 sites in Hungary
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A Virus, H7N9 Subtype
Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
H7N9 viruses have caused an outbreak of severe respiratory disease in 2013-2014 in China that affected many older adults. This study will evaluate the safety of and immune response to a live attenuated H7N9 vaccine in adults 50…
- Trial name
- NCT02274545
- Testing
- H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, H1N1 Influenza
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and…
- Conditions
- Avian Influenza, H1N1 Influenza, Influenza
- Trial name
- NCT02921997
- Testing
- AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Subtype H5N1 Infection
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the…
- Trial name
- HIPCVAX-010S (NCT03701061)
- Testing
- Seasonal Influenza Vaccine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Pandemic Influenza
A/H5N1 Dose Ranging Study With Adjuvant Patch
This is a Phase 1/2, randomized, observer-blind, placebo-controlled clinical trial. A maximum of 500 eligible subjects in 10 groups will be enrolled, randomized and vaccinated in this study.
- Trial name
- NCT00532792
- Testing
- A/H5N1
- Where
- 5 sites in United States
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Influenza A Virus, H7N9 Subtype
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
H7N9 avian influenza (AI) viruses have caused a recent outbreak of severe respiratory disease in humans in China. The purpose of this study is to evaluate the safety and immunogenicity of a live attenuated H7N9 A/Anhui/13 ca…
- Trial name
- NCT01995695
- Testing
- Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Inactivated Influenza A/H5N1 Vaccine in the Elderly
The purpose of this research study is to compare how the body reacts to different strengths of a new H5N1 flu vaccine. Researchers will also look at how antibodies are made after subjects receive the H5N1 flu vaccine.
- Trial name
- NCT00230750
- Testing
- Influenza A/H5N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 261 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Virus Diseases
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
UMN-0501 is a purified recombinant influenza HA vaccine (A H5N1/Vietnam/1203/2004). The purpose of the present study is to evaluate immunogenicity, safety and optimal dose among three different doses of UMN-0501 following two…
- Trial name
- NCT00980447
- Testing
- UMN-0501
- Where
- 2 sites in Japan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza, Human, Influenza in Birds
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
This is a Phase 2, randomized, multi-center study in approximately 300 adults who received 2 doses of aH5N1c or placebo in and completed the parent study V89_18 in the <65 years of age cohort.
- Conditions
- Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections
- Trial name
- NCT05422326
- Testing
- aH5N6c on Day 1, aH5N6c on Day 22
- Where
- 18 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults
The purpose of this research study is to compare how the body reacts to different strengths of an H5N1 flu vaccine when given by different routes of injection (injection into the skin or into the muscle).
- Trial name
- NCT00310206
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)